Test of a TB vaccine for newborns in sub-Saharan Africa
Part of Infections clinical trials.
This Phase 3 study tests whether MTBVAC can safely protect newborn babies from tuberculosis and whether it helps the baby’s immune system learn to fight TB. If you enroll, the goal is to see safety and immune response in real newborn settings in sub-Saharan Africa.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be a newborn within 7 days of birth
- Your baby should be healthy at birth (based on history and an exam)
- Your baby’s birth weight must be at least 2,450 grams, and 5-minute Apgar score must be 7 or higher
- Your baby must be at least 37 weeks along (gestational age)
- Your mother must provide consent and allow the study team to check medical records
- Your baby must be followed by you for the whole study schedule and agree to trial visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests MTBVAC, a TB vaccine candidate, to see if it is safe and whether it helps the immune system. It may be a fit if you’re eligible for TB and HIV-related vaccine safety testing and can follow study visits and testing.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
This study is testing new ways to quickly diagnose TB in children under 15. It aims to find better tests that can be used at clinics, especially for kids who may not have obvious symptoms.
This study is testing a new way to diagnose TB in children using simple symptom checklists. It aims to see if these checklists can help doctors find TB earlier and more accurately, especially in children who are very young or have other health problems.
This trial tests whether providing tuberculosis preventive treatment at home, instead of at a clinic, can help protect children under 15 who live with an adult who has recently been diagnosed with pulmonary TB. The goal is to make it easier for families to access care and stop TB from spreading.
This study measures how strongly your immune system responds to COVID-19 vaccines. It includes people with newly diagnosed tuberculosis and a healthier comparison group, aiming to understand vaccine immune effects and safety.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.